Skip to main content

Abscess

6
Pipeline Programs
5
Companies
7
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

AbbVie
DALVANCEApproved
dalbavancin
AbbVie
intravenous2014
14M Part D

Competitive Landscape

5 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
3
1
DalbavancinPhase 31 trial
DalbavancinPhase 31 trial
IV DalbavancinPhase 31 trial
Active Trials
NCT02127970Completed698Est. Mar 2015
NCT01339091Completed573Est. Nov 2012
NCT01431339Completed739Est. Dec 2012
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
FentanylPhase 41 trial
Active Trials
NCT01881997Withdrawn0Est. Dec 2011
Bayer
BayerLEVERKUSEN, Germany
1 program
1
MoxifloxacinPhase 3Small Molecule1 trial
Active Trials
NCT00402727Completed813Est. Jun 2008
Shield Therapeutics
Shield TherapeuticsMA - Wellesley
1 program
Trimethoprim-sulfamethoxazoleN/ASmall Molecule1 trial
Active Trials
NCT00867789Terminated140Est. Oct 2012
Bryan Corporation
Bryan CorporationOH - Cincinnati
1 program
incision and loop drainageN/A1 trial
Active Trials
NCT04241471Withdrawn0Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles TherapeuticsFentanyl
AbbVieDalbavancin
AbbVieIV Dalbavancin
AbbVieDalbavancin
BayerMoxifloxacin
Bryan Corporationincision and loop drainage
Shield TherapeuticsTrimethoprim-sulfamethoxazole

Clinical Trials (7)

Total enrollment: 2,963 patients across 7 trials

NCT01881997Angeles TherapeuticsFentanyl

Pain Management in ED for Incision and Drainage of Abscess

Start: Jun 2011Est. completion: Dec 20110
Phase 4Withdrawn
NCT02127970AbbVieDalbavancin

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Start: Apr 2014Est. completion: Mar 2015698 patients
Phase 3Completed
NCT01431339AbbVieIV Dalbavancin

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Start: Jul 2011Est. completion: Dec 2012739 patients
Phase 3Completed
NCT01339091AbbVieDalbavancin

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Start: Mar 2011Est. completion: Nov 2012573 patients
Phase 3Completed
NCT00402727BayerMoxifloxacin

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

Start: Sep 2006Est. completion: Jun 2008813 patients
Phase 3Completed
NCT04241471Bryan Corporationincision and loop drainage

Incision and Loop Drainage Utilizing a Novel Technique for Management of Cutaneous Abscess in an Adult Population

Start: May 2020Est. completion: Feb 20210
N/AWithdrawn
NCT00867789Shield TherapeuticsTrimethoprim-sulfamethoxazole

Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department

Start: Mar 2009Est. completion: Oct 2012140 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.